Challenges in the microbiological diagnosis and management of hVISA infections

Pathology

Volumn 43, Issue 4, 2011, Pages 357-361

  Cheong, Wan Sai J ^a   Harris, Patrick ^a   Oman, Kimberly ^a   Norton, Robert ^a  

^a TOWNSVILLE HOSPITAL   (Australia)

Author keywords

HVISA; Vancomycin resistance; VISA

Indexed keywords

EID: 80052207658     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283464ca3     Document Type: Article

References (26)

1. Samra Z, Gadba R, Ofir O. Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at three periods during 1991-1997. Eur J Clin Microbiol Infect Dis 2001; 20: 425-7. (Pubitemid 32646368)
2. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
3. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillinresistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009; 53: 3447-52.
4. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200. (Pubitemid 351269157)
5. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin- intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
6. Sievert DM, Rudrik JT, Patel JB, McDonald LC,Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002- 2006. Clin Infect Dis 2008; 46: 668-74. (Pubitemid 351321548)
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillinresistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6. (Pubitemid 27341646)
8. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
9. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55. (Pubitemid 33586048)
10. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 (Suppl 1): S25-34. (Pubitemid 41832062)
11. Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14. (Pubitemid 36098547)
12. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007; 45: 1511-4. (Pubitemid 46762406)
13. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65: 1015-8.
14. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28: 983-7.
15. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard, 7th edition. Wayne, PA: CLSI, 2009; CLSI document M7-A8.
16. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-44. (Pubitemid 32606216)
17. Marlowe EM, Cohen MD, Hindler JF, Ward KW, Bruckner DA. Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J Clin Microbiol 2001; 39: 2637-9. (Pubitemid 32606246)
18. Wootton M, Howe RA, Hillman R,Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403. (Pubitemid 32303403)
19. Jorgensen JH, Crawford SA. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 2006; 44: 2126-9. (Pubitemid 43902163)
20. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. Wayne, PA: CLSI, 2010; CLSI document M100-S19.
21. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 329-32.
22. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 2009; 31: 1936-45.
23. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9: 617-24.
24. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin- intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008; 46: 1132-6.
25. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009; 63: 489-92.
26. Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J ClinMicrobiol 2008; 46: 3042-7.